Biblio
Export 2446 results:
Author Title Type [ Year] Filters: First Letter Of Keyword is A [Clear All Filters]
“Cognitive, Functional, and Emotional Changes During the COVID-19 Pandemic in Greek Patients with Neurocognitive Disorders.”, J Alzheimers Dis, vol. 88, no. 2, pp. 537-547, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 691-699, 2022.
, “Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil.”, J Alzheimers Dis, vol. 90, no. 1, pp. 161-172, 2022.
, “Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil.”, J Alzheimers Dis, vol. 90, no. 1, pp. 161-172, 2022.
, “Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil.”, J Alzheimers Dis, vol. 90, no. 1, pp. 161-172, 2022.
, “A Comparison of Well-Being of Carers of People with Dementia and Their Ability to Manage Before and During the COVID-19 Pandemic: Findings from the IDEAL Study.”, J Alzheimers Dis, vol. 88, no. 2, pp. 679-692, 2022.
, “The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1321-1328, 2022.
, “The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1321-1328, 2022.
, “The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1321-1328, 2022.
, “The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1321-1328, 2022.
, “COVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences.”, J Alzheimers Dis, vol. 88, no. 2, pp. 399-416, 2022.
, “Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.”, J Alzheimers Dis, vol. 88, no. 2, pp. 577-588, 2022.
, “Detecting Alzheimer's Disease Using Natural Language Processing of Referential Communication Task Transcripts.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1385-1398, 2022.
, “Detecting Alzheimer's Disease Using Natural Language Processing of Referential Communication Task Transcripts.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1385-1398, 2022.
, “Diabetic Retinopathy Predicts Risk of Alzheimer's Disease: A Danish Registry-Based Nationwide Cohort Study.”, J Alzheimers Dis, vol. 86, no. 1, pp. 451-460, 2022.
, “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
, “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
, “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
, “Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 1, pp. 443-456, 2022.
, ,